Study of Artesunate in Metastatic Breast Cancer
This trial is active, not recruiting.
|Conditions||metastatic breast cancer, locally advanced breast cancer|
|Collaborator||H. W. & J. Hector-Stiftung, Weinheim|
|Start date||October 2008|
|End date||August 2011|
|Trial size||30 participants|
|Trial identifier||NCT00764036, EUDRACT 2007-004432-23, M33/2|
The purpose of this study is to evaluation the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced breast cancer.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Dose limiting adverse events with possible, probable or definite relation with the respective dose level of the add-on therapy
time frame: 8-12 weeks
Adverse events, relation between adverse events and add-on therapy, cortisol profile in saliva, overall response rate, clinical benefit, assessment of patients expectations
time frame: 8-12 weeks
Female participants at least 18 years old.
Inclusion Criteria: - Patients with histologically or cytologically confirmed breast cancer - Distant metastases or locally advanced breast cancer - Age ≥ 18 years - ECOG performance ≤ 2 - Life expectancy of at least 6 months - Written informed consent - individual standard therapy according to guidelines - Oral intake of trial medication possible - Compliance with study procedures - Women of childbearing potential: negative pregnancy test before start of medication - Use of a highly effective method of birth control during intake of add-on therapy for women of childbearing potential being sexually active Exclusion Criteria: - Allergy to artesunate or to other artemisinin derivatives - Concurrent conditions interfering with patient safety - Communication problems - Concurrent participation in another clinical trial or 4 weeks prior to recruitment - Participation in a clinical trial with an unapproved drug 6 months prior to recruitment - Sinus bradycardia, bradyarrhythmia - AV-Block II° and III° - QTc > 500 msec - Previously known long QT-syndrome - Concurrent intake of a medication with clinically relevant neurotoxicity or during 30 days prior to recruitment - Relevant neurological symptoms which might complicate the evaluation of the compatibility of the IMPD (f. e. cerebral metastases) or might be subject to worsening during intake of the IMPD - Radiotherapy 2 weeks prior of the intake of the IMPD - Concurrent intake of supplements or any other medication with unapproved efficacy f.e. vitamins, minerals or others (OTC) - Pregnancy and lactation - Ineffective mode of contraception in women of childbearing potential
|Official title||Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer|
|Principal investigator||Cornelia U v. Hagens, MD|
|Description||Additional objectives are: - parallel sampling of blood and saliva for the determination of drug concentrations and pharmacokinetic parameters in a substudy on the day of first application and during steady state - attempt to establish a therapeutical drug monitoring|
Call for more information